Powered by WPeMatico
Powered by WPeMatico
Kolkata: The Medical Counselling Committee (MCC) recently published the MBBS seat matrix for the academic year 2025-26, confirming a total of 5,699 MBBS seats across 38 medical colleges in West Bengal. These seats will be available for NEET UG 2025 aspirants participating in the centralised counselling process.
This year’s matrix includes a mix of government, private, and semi-government institutions. Leading the seat count are government colleges such as Calcutta National Medical College, Nil Ratan Sircar Medical College, and RG Kar Medical College, each offering around 249–250 seats.
Several newly established colleges, including Barasat, Krishnanagar, Jhargram, Tamralipta, and Uluberia Government Medical Colleges, have been allocated 100 seats each
Private and self-financed institutions like IQ City Medical College (250 seats), JIS School of Medical Science and Research (150), and Gauri Devi Institute of Medical Sciences, Durgapur (200) also play a key role in supplementing the state’s overall seat availability. Institutions of national importance such as AIIMS Kalyani and ESIC Medical College, Joka are part of the list, contributing 125 seats each.
West Bengal Medical Colleges & MBBS Seats (2025)
| S.No. | Name of college | No. of seats for AY 2025-26 |
| 1 | All lndia lnstitute of Medical Sciences, Kalyani, Nadia |
125 |
| 2 | Bankura Sammilani Medical College, Bankura |
200 |
| 3 | Barasat Government Medical College and Hospital, Banamalipur, West Bengal |
100 |
| 4 | Burdwan Medical College, Burdwan | 200 |
| 5 | Calcutta National Medical College, Kolkata | 250 |
| 6 | College of Medicine and JNM Hospital,KaIyani,Nadia | 125 |
| 7 | College al Medicine and Sagore Dutta Hospital, Kolkata |
125 |
| 8 | Caochbehar Government Medical College & Hospital, Coachbehar, WB |
100 |
| 9 | Diamond Harbour Government Medical College and Hospital, West Bengal |
100 |
| 10 | EAST WEST INSTITUTE OF MEDICAL SCIENCES AND RESEARCH | 50 |
| 11 | Employees State Insurance Corporation Medical College, Joka, Kolkata |
125 |
| 12 | Gauri Devi Institute of Medical Sciences and Hospital, Durgapur |
200 |
| 13 | Govt. Medical College, Kolkata | 250 |
| 14 | ICARE Institute of Medical Sciences & Research, Haldia, Purba Midanpore | 150 |
| 15 | Institute of Postgraduate Medical Education & Research, Kolkata |
200 |
| 16 | IQ-City Medical College, Burdwan | 250 |
| 17 | JAGANNATH GUPTA INSTITUTE OF MEDICAL SCIENCES AND HOSPITAL | 200 |
| 18 | JAKIR HOSSAIN MEDICAL COLLEGE AND RESEARCH INSTITUTE |
50 |
| 19 | Jalpaiguri Government Medical College and Hospital, Jalpaiguri, West Bengal | 100 |
| 20 | Jhargram Government Medical College And Hospital, WB | 100 |
| 21 | JIS School Medical Science and Research, Howrah, WB | 150 |
| 22 | JMN Medical College, Nadia, West Bengal | 150 |
| 23 | KPC Medical Callege,Jadavpur,Kolkata | 200 |
| 24 | Krishnanagar Institute of Medical Science, Nadia, West Bengal |
100 |
| 25 | Malda Medical College & Hospital, Malda | 125 |
| 26 | Midnapore Medical College, Midnapare | 200 |
| 27 | Murshidabad Medical College & Hospitals, Murshidabad | 125 |
| 28 | Nilratan Sircar Medical College, Kolkata |
250 |
| 29 | North Bengal Medical College, Darjeeling | 200 |
| 30 | Prafulla Chandra Sen Government Medical College and Hospital | 100 |
| 31 | Purulia Government Medical College & Hospital | 100 |
| 32 | Raiganj Government Medical College & Hospital, Raiganj | 100 |
| 33 | Rampurhat Government Medical College & Hospital, Rampurhat | 100 |
| 34 | RG Kar Medical College, Kolkata | 249 |
| 35 | SANTINIKETAN MEDICAL COLLEGE | 150 |
| 36 | Sarat Chandra Chattopadhyay Government Medical College & Hospital, Uluberia |
100 |
| 37 | Shri Ramkrishna Institute of Medical Sciences & Sanaka Hospitals, Durgapur |
200 |
| 38 | Tamralipta Government Medical College & Hospital | 100 |
| Total seats | 5699 | |
NEET-UG SCHEDULE- 2025
|
S.NO. |
SCHEDULE FOR ADMISSION |
ALL INDIA QUOTA/DEEMED/CENTRAL UNIVERSITIES |
VERIFICATION OF JOINED CANDIDATES’ DATA BY MCC |
STATE COUNSELLING |
VERIFICATION OF JOINED CANDIDATES |
|
1 |
1st Round of Counselling |
21st July 2025 to 9th August 2025 |
19th to 20th August 2025 |
9th to 18th August 2025 |
25th to 26th August 2025 |
|
2 |
Last date of Joining |
18th August 2025 |
24th August 2025 |
||
|
3 |
2nd round of Counselling |
21st to 29th August 2025 |
6th to 8th September 2025 |
27th August 2025 to 5th September 2025 |
12th to 13th September 2025 |
|
4 |
Last date of joining |
5th September 2025 |
11th Sept, 2025 |
||
|
5 |
Round-3 |
9th to 17th September 2025 |
26th 28th September 2025 |
15th to 25th September 2025 |
1st October 2025 |
|
6 |
Last date of joining |
25th September 2025 |
30th September 2025 |
||
|
7. |
Stray Vacancy |
30th September 2025 to 4th October 2025 |
2nd to 5th October 2025 |
10th October 2025 |
|
|
8. |
Last date of joining |
10th October 2025 |
10th October 2025 |
||
|
9. |
Commencement of Academic Session for UG Courses |
5th September, 2025` |
|||
Powered by WPeMatico
Raipur: The Chhattisgarh High Court has taken serious note of recent media reports highlighting alarming
conditions at government hospitals across the state, particularly in Raipur,
and has directed the state’s Health Secretary to submit a personal affidavit
addressing the concerns. The matter will be heard again on August 12, 2025.
The case, initially
scheduled for August following its last hearing on June 10, 2025, was brought
forward after a Hindi daily carried a detailed report on July 13, exposing
severe lapses in public healthcare. “The worst AIIMS! From resignation to see
the doctor, it took 48 hours. It is a headache to get a test done,” the report
mentioned.
The report described long
queues and excessive waiting times at AIIMS Raipur, where patients reportedly
have to wait up to 48 hours after registration to meet a doctor. Surgeries are
being delayed by four months, and X-ray services involve a wait of nearly three
hours. Given that most residents cannot afford private care, these delays are
said to cause unnecessary suffering.
Another news, published
on 24.07.2025 in Navbharat, portrayed a very horrific situation, and it raised a serious question on the functioning of the Health
Department of the State as well as the CGMSC. The aforesaid news stated that the pregnancy kit, which gives faulty results, is being distributed. It has
been reported that the company that supplied the defective materials has been
directed not to supply any further materials, but still, inferior quality
surgical items and medicines are being supplied. Some of the lifesaving drugs, which have been found to be of substandard quality and failing in laboratory
tests, are also being supplied.
There is yet another news
published in Haribhoomi which is in respect of a Community Health Centre of
Bilha Block, District Bilaspur, and the situation at CHC Bilha was also
criticised in it, with claims that although 15 doctors are on the roster, no doctors
were present until 11 a.m. on August 4, forcing more than 250 patients to wait
for hours. Specialist doctors in gynaecology, orthopaedics, dentistry, and
paediatrics were reportedly unavailable, and an X-ray machine has been unused
for a year.
The court was further
informed that the surgical ward remains avoided by patients due to the absence
of doctors during the night, despite a 24-hour duty requirement. Additionally,
“Hamar Lab” — a facility set up with lakhs of rupees to perform 71 diagnostic
tests — is barely functional due to a shortage of reagents from CGMSC, limiting
it to 11–12 tests at present. Taking a stern view, the court said the
situation, if accurate, reflects poorly on the functioning of the state’s
Health Department and CGMSC. It has sought a detailed explanation from the
Health Secretary before the next hearing.
To view the official order, click on the link below:
Powered by WPeMatico
New Delhi: The Indian pharmaceutical market (IPM) registered a growth of 7.9 percent in July 2025, and cardiac and anti-diabetes therapy segments have shown strong volume, according to a report by market research firm Pharmarack.
Cardiac and anti-diabetes, which together contribute nearly 25% of the overall domestic market– recorded value growth of 14.1% and 9% respectively.
Several super groups, such as urology and antineoplastics, each contributing around 2 per cent to the IPM’s monthly sales value, also reported double-digit value growth. The respiratory segment also registered a 9.2 per cent value growth, IANS reported.
“New introductions and price growth have driven the market growth for the month of July for most of the therapies,” said Sheetal Sapale, vice-president (commercial) at Pharmarack.
“Among the top therapies, only cardiac and anti-infectives have a strong volume growth. New introductions also drove the growth in the anti-diabetes segment,” Sapale added.
Meanwhile, the report highlighted that the GLP-1 agonists market continues to ride on a strong positive trend.
As per the report, Semaglutide and Tirzepatide continue to drive the growth of this market.
While Semaglutide is marketed as Rybelsus (oral), Wegovy (injections), Tirzepatide is sold under the brand Mounjaro. Both injectable medications are used to treat type 2 diabetes and promote weight loss.
“A strong upward momentum is seen for the month of July. This may be due to aggressive promotion of both the new launch brands in the market,” Sapale said.
Although the launch of Tirzepatide had impacted Semaglutide (Rybelsus), “we see Wegovy bringing back the molecule on a strong sales momentum,” Sapale said.
Further, the report also focused on strategic areas that drive exponential growth in the Indian pharma industry. This includes biologics and biosimilars, which are changing the canvas of the Indian pharma market.
“The biosimilars market is about Rs 3,900 Crore market today, growing at a five-year CAGR of 15 per cent,” Sapale said.
“With the changing landscape of disease patterns and associated complications, Biologics and Biosimilars play a critical role in the Indian pharma market,” Sapale added.
Powered by WPeMatico
Hyderabad: Aragen, a global Contract Research, Development and Manufacturing Organization (CRDMO), has announced the appointment of Aniel Khubchandani as CEO of its Development & Manufacturing Solutions business. Aniel will be a member of Aragen’s Management Council and will be based in Hyderabad.
Commenting on the appointment, Manni Kantipudi, Chief Executive Officer, Aragen Life Sciences, said, “I am happy to welcome Aniel to Aragen and have him in the Management Council. Development and Manufacturing Solutions is a critical vertical with tremendous potential to significantly scale up. Aniel brings over 30 years of leadership experience in pharmaceuticals and specialty chemicals, with deep expertise in life sciences, commercial operations, and strategic initiatives, to lead this journey.”
Aniel Khubchandani said, “I am excited to join Aragen and lead its development and manufacturing business. Globally, there is an increasing focus on outsourcing, especially in the late phase and commercial manufacturing space. In the past few years, Aragen has made strategic investments to strengthen its capabilities and expand its capacity in the development and manufacturing vertical, and is on the cusp of scaling to the next level of growth. I thank the Board for giving me an opportunity to be a part of this exciting journey.”
Before joining Aragen, Aniel was the CEO of Sekhmet Pharmaventures and Co-CEO at Jubilant Ingrevia Limited, where he successfully led significant business transformations and growth strategies. His extensive experience includes organic growth initiatives, mergers & acquisitions, B2B digital marketing, enterprise risk management, licensing, and strategic execution. He also worked at Duncans Industries, Vam Organic Chemicals Ltd, and Bindal Agro Chemicals Ltd.
He is a certified Independent Director (IICA), a Six Sigma Black Belt, and an alumnus of IIT, IIM, and the Kellogg School of Management.
Aragen Life Sciences is a globally renowned R&D and manufacturing solutions provider to the global life sciences industries. It offers a range of solutions across the drug discovery, development and manufacturing continuum to advance small and large-molecule programs. The Company operates through a global network of six sites with a team of ~4500 employees and 450+ PhDs. Its expertise and experience have enabled over 400 customers to advance their research programs from early discovery through development and commercialization.
Powered by WPeMatico
Guwahati: The All India Institute of Medical Sciences (AIIMS Guwahati) has invited online applications for the Faculty post on a Contract Basis.
AIIMS Guwahati, an autonomous Institute of National Importance under the Ministry of Health & Family Welfare – Government of India, was established under the Pradhan Mantri Swasthya Suraksha Yojna (PMSSY) in May 2017. The foundation stone of the Institute was laid by the Honourable Prime Minister Shri Narendra Modi on May 26, 2017.
The Vacancies are in the Department of Anaesthesiology and General Surgery.
1. Application Process: Interested candidates, fulfilling all the eligibility criteria, may report for a Walk-in Interview along with the application in a prescribed format with duly self-attested copies of certificates/ testimonials with regards to qualifications & experience and bring original certificates/ testimonials etc. by 08:30 AM on the date of Walk-in-interview. A soft copy of the application must be sent to the following email: recruitment-cell@aiimsguwahati.ac.in
2. Candidates are advised to fill their correct and active e-mail ID in the application as per the prescribed format, as all correspondences will be made by the Institute through e-mail.
3. The candidate must ensure that their photo and signature should be clearly visible in the application.
4. In case a candidate wishes to apply for more than one post, he/she is required to fill in the form separately and separate application fees as applicable to be paid.
5. Tenure: The appointment is for a period of 01 year or till the time the post is filled on a regular basis whichever is earlier. Further extension in exigency of the services may be considered by the Competent Authority as admissible under the rules. The engagement will be purely on contractual basis, and it will not bestow any rights implicitly upon the candidate to claim any permanent absorption or any liability by the AIIMS, Guwahati on termination of contract. However, the initial tenure of engagement can be less than one year as per the decision of the Competent Authority.
Powered by WPeMatico
New Delhi: The Medical Counselling Committee (MCC) of the Directorate General of Health Services (DGHS) has the responsibility to conduct counselling for 100% seats of super-speciality courses across the country, the Union Minister of State for Health, Smt Anupriya Patel, informed the Lok Sabha.
MoS Health clarified that the Supreme Court has granted a 50% reservation for the in-service candidates in Tamil Nadu and the counselling for the AIQ seats by MCC and in-service seats by the SSC, Tamil Nadu, is carried out in tandem.
The Minister provided this clarification while responding to the queries raised by Smt. Kanimozhi Karunanidhi, who sought to know whether the Government is aware that 145 of the 215 super speciality seats reserved for in-service candidates under the Tamil Nadu State quota were prematurely surrendered to the All India Quota without conducting the mandatory second round of State counselling.
She further sought to know the reasons for not approving or notifying the Round 2 counselling schedule for Tamil Nadu despite timely requests from the State government, whether this action violated the Supreme Court’s directions regarding the 50% reservation for in-service doctors in super speciality courses. She also asked the Ministry whether the Government is likely to consider restoring the surrendered seats and allow Round-2 counselling in Tamil Nadu, and the steps being taken by the Government to avoid such procedural lapses in future and ensure fair and consistent implementation of the Super Speciality counselling process across all States.
Responding to these queries, the Minister informed that the Medical Counselling Committee (MCC) of Directorate General of Health Services (DGHS) has been entrusted with the responsibilty to conduct counselling for 100% seats of Super Specialty (SS) courses across the country
“In accordance with the Hon’ble Supreme Court’s order dated 16th March 2022 in Writ Petition (Civil) No. 53 of 2022 titled as N. Karthikeyan & Ors. vs. State of Tamil Nadu & Ors., a 50% reservation for in-service candidates has been granted in the state of Tamil Nadu. The State Selection Committee (SSC) of Tamil Nadu is responsible for conducting counselling for these reserved seats,” further informed the Minister.
“Counselling for All India Quota (AIQ) seats by MCC and in-service seats by the SSC, Tamil Nadu is carried out in tandem, with each round of All India counselling immediately followed by the respective round of in-service counselling,” the Minister added.
Minister Patel further informed that during SS Counselling 2024, after the completion of Round-1 of in-service counselling, the SSC, Tamil Nadu surrendered the unfilled in-service seats to MCC.
“These seats were merged into the AIQ seat matrix for Round-2. After completion of Round-2 of All India counselling, the remaining in-service seats were returned to the State to proceed with Round-2 of inservice counselling. Further, data of candidates made eligible after percentile reduction was also forwarded to the State for conducting stray round of in-service seats,” informed the Minister.
Medical Dialogues had earlier reported that last year TN Health Department had announced that it would henceforth decide regarding the number of seats to be reserved for them on a year-on-year basis. Issuing a G.O. the State Health Department had mentioned that the number of seats reserved in Postgraduate (MD/MS) admissions for the in-service candidates will be decided dynamically on a year-on-year basis.
The Health Department further stated in the order that for the academic year 2024-2025, the service reservation of PG seats for specialities other than General Medicine, General Surgery, Paediatrics, Obstetrics and Gynaecology, Orthopaedics, Anaesthesiology, Chest Medicine, Radiology, Community Medicine and Forensic Medicine will be kept in abeyance for a year.
Powered by WPeMatico
Puducherry: The Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER) Puducherry has officially joined the Government of India’s flagship initiative – Mission Karmayogi, by establishing its own Capacity Building Unit (CBU).
This step aligns with the directives of the Capacity Building Commission (CBC) and the Department of Personnel and Training (DoPT), Government of India.
Dr Stuti Verma, Consultant, Capacity Building, Training Division, Ministry of Health & Family Welfare, has guided and mentored JIPMER in establishing the JIPMER CBC division and in her note, she said that Mission Karmayogi aims to transform the capacity and mindset of public servants by promoting a citizen-centric, accountable, and service-oriented workforce rooted in Indian values. Dr. Stuti added that CBC at its core, envisions a shift from a rule-based to a role-based approach in training and performance, ensuring that public service delivery becomes more efficient, effective, and empathetic.
Dr. Vir Singh Negi, Director, JIPMER, said that the JIPMER CBU has been set up with the vision to instill a culture of excellence and selfless service (Seva Bhav) among its employees. It is working towards fostering a professional environment where continuous learning, personal development, and leadership are integral. Training initiatives under the CBU are designed to enhance not only professional competence but also personal well-being, including stress management and innovative, solution-driven thinking.
As part of this initiative, Mr. S. Rangabashiam, Deputy Director (Administration), Dr. Kusa Kumar Shaha, Dean (Karaikal), and Dr. Madhusudhanan Ponnusamy, Associate Dean (Academic), recently completed an intensive 5-day Lead Trainer Program conducted by the Capacity Building Commission in Delhi NCR. Following this, they successfully organized a 3-day training session at JIPMER to prepare 32 Master Trainers (Karmayogi Facilitators).
These Master Trainers will now lead a series of one-day Rashtriya Karmayogi programs across JIPMER’s three campuses, with the aim of reaching and empowering all employees to embrace the ethos of Mission Karmayogi — transforming from Karmachari (traditional employee) to Karmayogi (purpose-driven professional).
Dr. Vir Singh Negi, Director, JIPMER, added saying that through the structured implementation of Mission Karmayogi, JIPMER seeks to further augment its institutional ethos of professionalism, empathy, and accountability.
The capacity-building initiatives are envisioned to enhance service delivery by fostering a workforce that not only upholds clinical excellence but also demonstrates a high degree of sensitivity and responsiveness in patient care. This forward-looking approach is expected to reinforce JIPMER’s long-standing commitment to delivering holistic, patient-centered healthcare of the highest standards.
Powered by WPeMatico
Hyderabad: Sales of weight-loss drugs Wegovy by Danish pharmaceutical giant Novo Nordisk and Mounjaro by U.S.-based Eli Lilly doubled in India in July from a month earlier, according to data from research firm Pharmarack.
The surge reflects rapidly growing demand for these blockbuster anti-obesity treatments in the world’s most populous country,.
Wegovy, which was launched locally in June, saw its sales more than double to 5,000 units or 70 million rupees ($798,230) in July, the data showed.
Powered by WPeMatico
